featured
Outcomes of Treatment With Dupilumab for Up to 5 Years in Adults With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study
JAMA Dermatol 2024 Jul 10;[EPub Ahead of Print], LA Beck, R Bissonnette, M Deleuran, T Nakahara, R Galus, A Coleman, G Gherardi, J Xiao, R Dingman, C Xu, E Avetisova, A Dubost-Brama, A ShabbirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.